Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260

NCT03117309 is registered in ClinicalTrials.gov with Michael B. Atkins, MD as lead sponsor.

NCT NCT03117309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03117309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Lead sponsor
Michael B. Atkins, MD
Phase
Phase 2
Overall status
Completed
Start date
April 24, 2017
Completion date
January 23, 2025
Enrollment
164 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma